rHuEpo is pharmaceutical used to correct anemias associated with renal insufficiency, cancer and other diseases. Efforts to increase its efficacy in vivo by manipulating the protein’s structure resulted in novel Epo like agents. Epo mimetic agents and agents to increase endogenous production are underway. As Epo has tissue protective actions outside of erythropoiesis, designs try producing erythro-inactive molecules that still retain extra-hematopoietic activity. Data that Epo can trigger signaling in some cancer cells has raised attention of medical community and regulatory authorities.
COBISS.SI-ID: 24260313
Prolonged exposure to estrogens is a significant risk factor for the development of breast cancer, exerted by stimulating cell proliferation or through oxidative metabolism. In aim to provide a better understanding of estrogen metabolism in breast cancer, we determined the expression profiles of the genes for the estrogen and progesterone receptors, and for 18 estrogen-metabolizing enzymes in eight breast cancer cell lines. Our data show that the cell lines examined provide the full range of model systems and should further be compared with the expression profiles of breast cancer specimens.
COBISS.SI-ID: 27777753
The level of endogenous Epo (eEpo) is affected by hypoxia, anaemia, application of recombinant erythropoietin (rHuEpo), chemotherapy and others. Isoelectric focusing (IEF) combined with double immunobloting is a method that enables distinct analysis of eEpo and rHuEpo isoforms. Aim of our study was to set up method to analyse the chemotherapy and rHuEpo treatment effects on the pattern of eEpo in anaemic breast cancer patient. We confirmed that IEF enables to monitor the effects of treatment on the level of eEpo and indirectly indicates kidney function.
COBISS.SI-ID: 28208345
rHuEpo is used in medicine; it acts as a stimulus for production of red cells. Detection method that could differentiate between endogenous and exogenous Epo was developed in 2000, when the method called isoelectric focusing (IEF) was first used for detection of doping in sport. The problem of rHuEpo detection is structural similarity to endogenous Epo and low concentration of Epo in human blood and urine. IEF is currently not used as diagnostic method in clinical samples. It has potency to be used as method to identify the effects of rHuEpo and other therapy on endogenous Epo expression.
COBISS.SI-ID: 26200537